Published by Josh White on 25th March 2022
(Sharecast News) - Open Orphan announced on Friday that its hVIVO subsidiary has signed a £5m respiratory syncytial virus (RSV) human challenge study contract with an unnamed European biotechnology company, to test its intravenous antiviral candidate.
URL: http://www.digitallook.com/dl/news/story/32559286/...